People
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
The race toward a COVID-19 vaccine is focused around scientific development right now, but companies also need to be planning for manufacturing.
Numerous biopharma companies are testing or working to develop drugs and vaccines. But what is a bit unusual is the number of staffers at biotech and pharma companies and health care involved as participants in studies and clinical trials.
Researchers at the University of Maryland School of Medicine evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.
Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.
Convalescent and Therapeutic Antibodies and Older Vaccines Suggest Glimmers of Hope Against COVID-19
The amount of scientific information unearthed about SARS-CoV-2, the virus that causes COVID-19, in only six months is unprecedented. The speed is remarkable, although much of it will still need to be confirmed over time with more careful study. Still, each day presents new data with a glimmer of hope. Here’s a look at some recent findings.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”
The primary endpoint of the trial will be prevention of symptomatic COVID-19 disease, with key secondary endpoints including prevention of severe COVID-19, defined as hospitalization, and prevention of infection by SARS-CoV-2.
According to the report, at least 17 of this year’s 28 new drug shortages “are directly or indirectly prompted by events the current COVID-19 pandemic has brought on,” which includes the increased demand for anesthetics and other drugs used to facilitate intubation.
PRESS RELEASES